Siderophore 'Trojan Horse' Boosts Antibiotic Potency Against Resistant Klebsiella
- Chemists conjugated the beta-lactam antibiotic aztreonam to aerobactin, a bacterial iron-scavenging siderophore, exploiting bacteria's own iron-uptake machinery as a 'Trojan horse' to smuggle the drug inside cells.
- A modular synthetic route enabled controlled mono- and di-functionalization of aerobactin, with late-stage click-chemistry (CuAAC) attachment of payloads, providing a flexible platform applicable beyond this single conjugate.
- The lead monovalent conjugate was markedly more potent than aztreonam alone against a hypervirulent, clinically concerning Klebsiella pneumoniae strain, a substantial improvement over the parent antibiotic.
- Competition and iron-dependent activity studies confirmed delivery proceeds through the aerobactin iron-acquisition pathway, supporting genuine siderophore-mediated uptake rather than incidental potency gains.
- The results establish aerobactin as a viable scaffold for delivering antibacterial payloads against multidrug-resistant, hypervirulent Enterobacteriaceae.
Call this the cefiderocol playbook done cleaner. Aerobactin's a natural Fe(III) chelator with dedicated Klebsiella uptake receptors, so hijacking it to smuggle aztreonam past the outer membrane is exactly the kind of Trojan-horse logic that's already proven clinically viable — nice to see it extended to a hypervirulent strain, which is a genuinely scary unmet-need bug. What I like more, honestly, is the platform: modular mono-/di-functionalization plus late-stage CuAAC means this isn't a one-off heroic synthesis, it's a conjugation chassis I could point at other payloads. And they didn't just show a potency bump and wave hands — the competition/iron-dependence data actually nail down siderophore-pathway uptake, not some off-target membrane-permeabilization artifact. That's the control every conjugate paper should run but often skips.